Breast Tumor Articles & Analysis
9 articles found
Among the most promising strategies in this endeavor are the use of tumor models for breast cancer and the development of customized antibody-drug conjugates (ADCs). ...
Femtech World featured our partnership with PathPresenter to distribute the 4D Q-plasia OncoReader Breast within PathPresenter’s ClinPx Clinical Workflow Platform in their magazine. ...
The digital pathology software company PathPresenter (Montville, New Jersey) and the precision oncology platform firm 4D Path have entered into a partnership that could improve the diagnostic accuracy of breast tumor profiling. PathPresenter has developed a digital workflow tool for clinicians, pathologists and pharma companies to aggregate medical data. ...
Clinicians can make better diagnostic and treatment decisions using the data obtained by next-generation sequencing (NGS) technologies. Breast cancers, for example, have typically been diagnosed using mammography, physical exam, and histology. ...
Advances in DNA sequencing technology have made it possible to extensively analyze the breast tumor genome and construct a catalog of gene mutations that may initiate or drive tumor progression. ...
Ionising radiation is an established etiological agent for breast cancer, but is also a therapeutic modality used in cancer treatment. The accumulation of deoxyribonucleic acid (DNA) damage and deficient DNA repair are considered susceptibility factors that predispose individuals to breast cancer development. In the present study, the genetic damage induced by gamma radiation and repair capacity ...
Reactivation of the ZBP1 gene has been reported in various human tumors. In this study, we identified a detailed molecular mechanism of ZBP1 transactivation in breast cancer cells. ...
Moreover, the transcript is stabilized in breast cancer cells and overexpressed in human breast tumors. Finally, knockdown experiments showed that, in humans, 91H, rather than affecting H19 expression, regulates IGF2 expression in ...
Here, the crossing of ApcMin with cyclin D1–/– mice reduced the intestinal tumor number in animals genetically heterozygous or nullizygous for cyclin D1. Decreased tumor number in the duodenum, intestines, and colons of ApcMin/cyclin D1+/– mice correlated with reduced cellular proliferation and increased differentiation. ...